These engineered exosomes were capable of selectively delivering KRAS siRNA to non-small cell lung cancer cells that expressed the αvβ3 integrin, effectively downregulating the KRAS gene, inhibiting tumor proliferation, and demonstrating negligible toxicity. The gene discussed is KRAS; the disease is small cell lung carcinoma.